Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL8172708 | 0.98 | IDO1 (0.48) | IDO1CYP26A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL13504115 | 0.92 | OPRK1 (0.51) | — | |
| SCHEMBL3365060 | 0.92 | LTA4H (0.51) | IDO1 | |
| SCHEMBL3367622 | 0.92 | LTA4H (0.48) | IDO1 | |
| SCHEMBL11465115 | 0.91 | CYP26A1 (0.43) | IDO1CYP26A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL5527859 | 0.91 | TAAR1 (0.48) | IDO1 | |
| SCHEMBL5527855 | 0.91 | TAAR1 (0.48) | IDO1 | |
| SCHEMBL5516474 | 0.91 | CYP26A1 (0.47) | CYP26A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL22023702 | 0.91 | HRH3 (0.52) | CYP26A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4349439 | 0.91 | KDM1A (0.44) | IDO1CYP26A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 345 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559703-B2 | Fragrance composition | GIVAUDAN SA (CH) | 2026-02-24 | — | — | US | claimed |
| EP-4655373-A1 | BIODEGRADABLE PERFUME COMPOSITION | Givaudan SA (CH) | 2025-12-03 | — | — | EP | claimed |
| WO-2025202258-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2025-10-02 | — | — | WO | claimed |
| EP-4532646-A1 | A FRAGRANCE MIXTURE (V) | Symrise AG (DE) | 2025-04-09 | — | — | EP | claimed |
| CN-119317696-A | Perfume mixture (V) | 西姆莱斯股份公司 | 2025-01-14 | — | — | CN | claimed |
| US-20240301331-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2024-09-12 | — | — | US | claimed |
| WO-2024156688-A1 | BIODEGRADABLE PERFUME COMPOSITION | GIVAUDAN SA (CH) | 2024-08-02 | — | — | WO | claimed |
| EP-4407019-A1 | BIODEGRADABLE PERFUME COMPOSITION | Givaudan SA (CH) | 2024-07-31 | — | — | EP | claimed |
| US-20240225971-A1 | 1,3-BUTYLENE GLYCOL COMPOSITIONS AND METHODS OF USE THEREOF | AGAIN BIO APS (DK) | 2024-07-11 | — | — | US | claimed |
| EP-4294906-A1 | IMPROVEMENT IN OR RELATING TO ORGANIC COMPOUNDS | Givaudan SA (CH) | 2023-12-27 | — | — | EP | claimed |
| US-20080247966-A1 | Compositions and Methods to Counteract Oral Malodour | GIVAUDAN SA (CH) | 2008-10-09 | — | — | US | claimed |
| EP-1968531-A2 | TOPICAL COMPOSITIONS FOR REDUCING SKIN IRRITATION | Givaudan SA (CH) | 2008-09-17 | — | — | EP | claimed |
| CN-101262843-A | Improvements in or related to organic compounds | GIVAUDAN SA (CH) | 2008-09-10 | — | — | CN | claimed |
| EP-1919566-A1 | COMPOSITIONS AND METHODS TO COUNTERACT ORAL MALODOUR | Givaudan SA (CH) | 2008-05-14 | — | — | EP | claimed |
| WO-2007030961-A2 | TOPICAL COMPOSITIONS FOR REDUCING SKIN IRRITATION | GIVAUDAN SA (CH) | 2007-03-22 | — | — | WO | claimed |
| WO-2007025401-A1 | COMPOSITIONS AND METHODS TO COUNTERACT ORAL MALODOUR | GIVAUDAN SA (CH) | 2007-03-08 | — | — | WO | claimed |
| US-20050042255-A1 | Fragrance and flavour compositions | GIVAUDAN SA (CH) | 2005-02-24 | — | — | US | claimed |
| EP-1401388-A2 | FRAGRANCE AND FLAVOUR COMPOSITIONS | Givaudan SA (CH) | 2004-03-31 | — | — | EP | claimed |
| WO-2003002084-A2 | FRAGRANCE AND FLAVOUR COMPOSITIONS | GIVAUDAN SA (CH) | 2003-01-09 | — | — | WO | claimed |
| EP-1269982-A1 | Fragrance and flavour compositions | Givaudan SA (CH) | 2003-01-02 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12559703-B2 | Fragrance composition | DHCR24, OPRD1, OR10J3 | IDO1 1640/4885CYP26A1 331/4885CA12 2491/4885 |
| US-20050042255-A1 | Fragrance and flavour compositions | C5, FAAH2, TRPA1 | IDO1 1241/4885CYP26A1 327/4885CA12 3520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.